Brokerages Set Aptose Biosciences Inc. (NASDAQ:APTO) Price Target at $19.80

Shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) have earned an average rating of “Buy” from the five research firms that are covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued a report on the stock in the last year is $19.80.

APTO has been the subject of several research reports. Piper Sandler restated an “overweight” rating and issued a $5.00 price target on shares of Aptose Biosciences in a research note on Wednesday, April 3rd. StockNews.com upgraded Aptose Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, March 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $23.00 price objective on shares of Aptose Biosciences in a research note on Wednesday, March 27th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in APTO. Texas Capital Bank Wealth Management Services Inc purchased a new stake in Aptose Biosciences during the fourth quarter worth approximately $32,000. Sequoia Financial Advisors LLC acquired a new position in shares of Aptose Biosciences in the 1st quarter valued at $27,000. Annandale Capital LLC grew its position in shares of Aptose Biosciences by 40.0% in the 3rd quarter. Annandale Capital LLC now owns 74,666 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 21,334 shares during the last quarter. Cetera Advisors LLC raised its stake in Aptose Biosciences by 40.1% during the 4th quarter. Cetera Advisors LLC now owns 86,827 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 24,847 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Aptose Biosciences by 3.6% in the first quarter. Renaissance Technologies LLC now owns 976,577 shares of the biotechnology company’s stock valued at $1,328,000 after acquiring an additional 33,952 shares during the last quarter. 26.62% of the stock is owned by institutional investors and hedge funds.

Aptose Biosciences Stock Down 3.1 %

APTO opened at $1.23 on Wednesday. The firm has a market cap of $19.33 million, a P/E ratio of -0.16 and a beta of 1.29. Aptose Biosciences has a 52 week low of $1.20 and a 52 week high of $8.70. The business has a fifty day simple moving average of $1.62 and a 200-day simple moving average of $2.16.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its earnings results on Tuesday, March 26th. The biotechnology company reported ($1.44) earnings per share for the quarter, beating the consensus estimate of ($1.48) by $0.04. Sell-side analysts expect that Aptose Biosciences will post -3.31 earnings per share for the current year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.